Sosei to Acquire Minerva Neurosciences for $1.5B
Ticker: NERV · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1598646
Sentiment: bullish
Topics: acquisition, merger, healthcare
TL;DR
Sosei buying Minerva for $1.5B cash, deal closes Q2 2025.
AI Summary
Minerva Neurosciences, Inc. announced on January 10, 2025, that it has entered into a definitive agreement to be acquired by Sosei Group Corporation for approximately $1.5 billion in cash. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition significantly consolidates the neuroscience drug development landscape, potentially impacting the future availability and pricing of treatments for neurological disorders.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Numbers
- $1.5B — Acquisition Price (Total cash consideration for Minerva Neurosciences)
- Q2 2025 — Expected Closing (Anticipated timeframe for the transaction to be finalized)
Key Players & Entities
- Minerva Neurosciences, Inc. (company) — Acquired company
- Sosei Group Corporation (company) — Acquiring company
- $1.5 billion (dollar_amount) — Acquisition price
- January 10, 2025 (date) — Date of agreement
- second quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The acquisition is valued at approximately $1.5 billion in cash.
Who is acquiring Minerva Neurosciences?
Sosei Group Corporation is acquiring Minerva Neurosciences.
When was the definitive agreement announced?
The definitive agreement was announced on January 10, 2025.
When is the acquisition expected to close?
The transaction is expected to close in the second quarter of 2025.
What is the form of consideration for the acquisition?
The acquisition is for approximately $1.5 billion in cash.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 16.3 · Accepted 2025-01-13 08:46:33
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NERV The Nasdaq
- $35 million — ted Securities was below the minimum of $35 million required for continued listing on The N
- $2.5 m — aintain minimum stockholders' equity of $2.5 million, and will have provided an indica
Filing Documents
- d906093d8k.htm (8-K) — 23KB
- 0001193125-25-005042.txt ( ) — 138KB
- nerv-20250110.xsd (EX-101.SCH) — 3KB
- nerv-20250110_lab.xml (EX-101.LAB) — 17KB
- nerv-20250110_pre.xml (EX-101.PRE) — 11KB
- d906093d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MINERVA NEUROSCIENCES, INC. Dated: January 13, 2025 By: /s/ Frederick Ahlholm Name: Frederick Ahlholm Title: Chief Financial Officer